Evidence map›Paper›PMID 31540519›Full record

ArticlePharmaceutics2019

Rational Development of Liposomal Hydrogels: A Strategy for Topical Vaginal Antiretroviral Drug Delivery in the Context of HIV Prevention.

Maria J Faria, Raul Machado, Artur Ribeiro, Hugo Gonçalves, Maria Elisabete C D Real Oliveira, Teresa Viseu, José das Neves, Marlene Lúcio

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Review
  3. Anti-Pharmaceutics · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Microencapsulation Techniques in HIV Pediatric Formulations: Advances and Future Outlook.Advances in pharmacological and pharmaceutical sciences · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Maria J FariaCF-UM-UP-Centro de Física das Universidades do Minho e Porto, Departamento de Física da Universidade do Minho, 4710-057 Braga, Portugal.
Raul MachadoCBMA-Centro de Biologia Molecular e Ambiental, Departamento de Biologia, Universidade do Minho, 4710-057 Braga, Portugal. raulmachado@bio.uminho.pt.ORCID 0000-0002-9477-9945
Artur RibeiroCEB-Centro de Engenharia Biológica, Universidade do Minho, 4710-057 Braga, Portugal. arturibeiro@ceb.uminho.pt.ORCID 0000-0003-3298-5564
Hugo GonçalvesParalab, SA, 4420-392 Valbom, Portugal. hugo.goncalves@paralab.pt.
Maria Elisabete C D Real OliveiraCF-UM-UP-Centro de Física das Universidades do Minho e Porto, Departamento de Física da Universidade do Minho, 4710-057 Braga, Portugal.ORCID 0000-0002-9728-8172
Teresa ViseuCF-UM-UP-Centro de Física das Universidades do Minho e Porto, Departamento de Física da Universidade do Minho, 4710-057 Braga, Portugal. tviseu@fisica.uminho.pt.
José das Nevesi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal. j.dasneves@ineb.up.pt.ORCID 0000-0002-2317-2759
Marlene LúcioCF-UM-UP-Centro de Física das Universidades do Minho e Porto, Departamento de Física da Universidade do Minho, 4710-057 Braga, Portugal. mlucio@fisica.uminho.pt.ORCID 0000-0003-2593-1672
University of Minho · PTParalab (Portugal) · PTUniversidade do Porto · PT

Funding

Fundação para a Ciência e a Tecnologia CTTI-150/18-CF(1)Fundação para a Ciência e a Tecnologia ERA-IB-2-6/0004/2014Fundação para a Ciência e a Tecnologia POCI-01-0145-FEDER-032651Fundação para a Ciência e a Tecnologia PTDC/ NAN-MAT/326512017Fundação para a Ciência e a Tecnologia PTDC/NAN-MAT/326512017Fundação para a Ciência e a Tecnologia UID/BIA/04050/2019Fundação para a Ciência e a Tecnologia UID/FIS/04650/2019Programa Gilead GÉNESE PGG/002/2016Programa Gilead GÉNESE PGG/046/2015
6 · The paper itself

Abstract

HIV/AIDS stands as a global burden, and vaginal microbicides constitute a promising strategy for topical pre-exposure prophylaxis. Preceding the development of a microbicide containing tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), in silico and in vitro studies were performed to evaluate the physicochemical characteristics of both drugs, and to study their biophysical impact in lipid model systems. Results from these pre-formulation studies defined hydrogels as adequate vehicles to incorporate TDF-loaded liposomes and FTC. After studying interactions with mucin, zwitterionic liposomes with a mean diameter of 134 ± 13 nm, an encapsulation TDF efficiency of approximately 84%, and a transition temperature of 41 °C were selected. The chosen liposomal formulation was non-cytotoxic to HEC-1-A and CaSki cells, and was able to favor TDF permeation across polysulfone membranes (

Indexed as

drug releaseemtricitabinehydrogelsliposomesmicrobicidesnanomedicinetenofovir disoproxil fumaratetopical PrEP

Identifiers

PMID31540519
PMCPMC6781289
OpenAlexW2973684455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.